Glucose Meters in Massachusetts

SiPhox Health is a Burlington, Massachusetts-based health diagnostics company specializing in silicon photonic biosensor technology for at-home blood testing and biomarker analysis. Founded in 2020 and backed by Y Combinator, Khosla Ventures, and Intel Capital, the company has delivered over 300,000 biomarker test results. SiPhox's proprietary EasyDraw kit enables painless upper-arm blood collection without needles or lab visits, with samples processed at CLIA-certified labs. The platform analyzes up to 60 biomarkers across cardiovascular, metabolic, hormonal, thyroid, liver, kidney, inflammation, and nutritional health. Beyond testing, SiPhox provides a centralized health dashboard with wearable integration (Apple Watch, Oura Ring, Fitbit), personalized supplement recommendations, lifestyle coaching, telehealth support, and an AI assistant (Sai) for result interpretation. The company targets chronic disease prevention and health optimization through evidence-based biomarker tracking and actionable insights.

Harvard Bioscience Inc is a holding company and distributor of laboratory and research equipment serving academic institutions, contract research organizations (CROs), pharmaceutical, and biotech companies. The company operates through multiple subsidiary brands including Data Sciences International (DSI), BTX Electroporation Systems, Multi Channel Systems (MCS), Biochrom, HEKA, Harvard Apparatus, Panlab, Warner Instruments, CMA Microdialysis, and Hugo Sachs Elektronik. Product portfolio encompasses electrophysiology systems (patch clamp amplifiers, multielectrode arrays, Ussing chambers), spectrophotometers and colorimeters (Ultrospec series, Biowave), amino acid analyzers, telemetry and behavioral monitoring systems, electroporation devices, and isolated organ perfusion systems. The company serves discovery, production, and regulatory compliance workflows for life-saving therapeutic development. Products include the INCUB8 multiwell MEA system for optical and electrophysiological recording, HEKA EPC 10 USB 3.0 patch clamp amplifier, IntraCell laser-based optoporation system, VivaMARS activity monitoring platform, Ponemah software (GLP and 21 CFR Part 11 compliant), continuous glucose telemetry for rodents, and various UV-Vis spectrophotometric instruments. The company actively participates in major scientific conferences including SfN, APS, ECS, and ISSCR, and maintains active engagement in neuroscience, cardiac, and translational research communities.

Medovate Limited is a UK-based medical device development and commercialization company specializing in bringing novel clinical innovations to market through structured partnerships with NHS clinicians and healthcare providers. The company operates across the full medical device development pipeline—from initial concept evaluation and clinical development through regulatory approval and global market launch. Medovate's current product portfolio includes Safira® (regional anesthesia injection safety system with automatic pressure limiting to reduce nerve injury risk), Glucosave® (critical care blood sampling safety device to prevent inappropriate insulin administration), Humidicare® (heat and moisture exchanger with visual alerts for mechanical ventilation circuits), LUMEVAC™ (endoscopic surgical device for management of life-threatening gastrointestinal tract infections), and CamPROBE (transperineal prostate biopsy facilitation device). The company leverages deep relationships with NHS institutions to validate medical needs, conduct clinical trials, and accelerate adoption of approved technologies. Medovate focuses on patient safety innovations and clinician-centered design, with demonstrated capability in securing regulatory clearance and driving market entry across multiple therapeutic domains including anesthesia, critical care, endoscopic surgery, and urology. The firm's model emphasizes unmet clinical needs resolution and cost-effective solutions for healthcare systems globally.

MyCareTeam develops MCT-Diabetes, a comprehensive diabetes monitoring and management platform designed to improve health outcomes and reduce overall healthcare costs. The solution facilitates communication and real-time monitoring between patients, caregivers, and healthcare professionals, enabling better disease management between clinical visits. MCT-Diabetes is marketed to three primary user groups: family caregivers seeking to support loved ones with diabetes regardless of location; healthcare professionals aiming to enhance patient quality of life through inter-visit monitoring and engagement; and organizations incorporating diabetes management into corporate wellness and employee health programs. The platform is offered on flexible monthly and yearly subscription models, making it accessible for individual and enterprise-level adoption.

Nova Biomedical is a privately held, globally-leading in vitro diagnostic (IVD) company founded in 1976 and headquartered in Waltham, Massachusetts. The largest privately owned diagnostic company in the United States, Nova Biomedical employs over 1,500 people across manufacturing facilities in Massachusetts and Taipei, Taiwan, serving 110+ countries through its global distributor network. The company specializes in advanced blood testing and analytical instrumentation, with a comprehensive portfolio including critical care blood gas analyzers (StatProfile® Prime series), point-of-care glucose meters (StatStrip®, NovaMax®), cell culture analyzers (BioProfile® Flex), clinical and bioprocessing osmometers, liquid volume verification systems, and automated CSF cell counters. Nova Biomedical serves hospitals, emergency departments, blood banks, biotech/pharmaceutical manufacturers, clinical research laboratories, and veterinary diagnostics markets. The company operates through multiple trusted brand portfolios including Advanced Instruments, BioProfile, StatProfile, StatStrip, Artel, Solentim, and GloCyte, delivering solutions for bioprocessing, clinical diagnostics, and veterinary applications with emphasis on improving patient outcomes and operational efficiency.